Participating Faculty

Published on: 
Supplements and Featured Publications, Treatment Strategies for Dyslipidemia, Volume 12, Issue 11 Suppl

The American Journal of Managed Care

This second part of a 3-part supplement series to addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.


Lori Funk, PharmD

Cape Fear Valley Health System

Fayetteville, North Carolina

Robert M. Guthrie, MD

College of Medicine and Public Health

Columbus, Ohio

Terrance Killilea, PharmD

Regence Blue Shield of Idaho

Professor Emeritus

President and Chief Executive Officer


Richmond, Virginia

Disclosure Statement

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

  • Robert M. Guthrie, MD Grant/Research support from: Abbott Laboratories Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline Consultant for: AstraZeneca Speaker's bureau/Honorarium: AstraZeneca

James M. McKenney, PharmD

Speaker's honoraria from:

  • AstraZeneca
  • Merck/Schering-Plough
  • Reliant

Research grant support from:

  • GlaxoSmithKline
  • Merck
  • Roche (research grant to National Clinical Research, Inc)
  • Takeda

Consulting services provided for:

  • KOS
  • Pfizer Sankyo

The following participants have declared no financial affiliations with corporate organizations:

  • Terrance Killilea, PharmD

We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).

The American Journal of Managed Care

Signed disclosures are on file at the office of , Princeton, New Jersey.


This publication was made possible by a grant from AstraZeneca.


The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.